Skip to main content
. 2016 Feb 15;4(1):5. doi: 10.3390/biomedicines4010005

Table 3.

Frequency of mild-to-moderate adverse events on days 3–7 (related or not to treatment) with artesunate-fansidar (AS/SP) in comparison with artesunate-amodiaquine (AS/AQ).

Event AS/SP (n = 83) AS/AQ (n = 86)
At least one adverse event 36 81
Abdominal pain 0 2
Cough 16 14
Catarrh 6 4
Diarrhoea 0 1
Dizziness 6 28
Anorexia 0 3
Fatigue 6 22
Nausea 2 4
Jaundice 0 3